A Randomized, Double-blind, Placebo-controlled, Phase III Confirmatory Study to Evaluate the Efficacy, Safety, Tolerability, and Antiviral Activity of Repeated Oral Administration of AK0529 in Hospitalized Infants with Respiratory Syncytial Virus Infection
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Ziresovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Ark Biosciences
- 21 Jan 2025 New trial record